Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany.

ABSTRACT:

Purpose

Systemic therapy choice for patients with recurrent and/or metastatic head and neck cancer (R/M HNC) is a challenge. Not much is known about systemic therapies used in daily clinical routine and their outcome.

Methods

Data of all 283 patients with R/M HNC (89.4% male, median age: 60 years) registered for first-line systemic therapy between 2015 and 2018 in the cancer registries of Thuringia, a federal state in Germany, were included. Patient characteristics and treatment patterns were summarized. Exploratory univariate and multivariate analyses were conducted on select of systemic therapy and prognostic factors for overall survival.

Results

The most frequent first-line regimens were platinum-based combinations (71.4%), mainly cetuximab + platinum + 5-fluoroura

SUBMITTER: Morkramer L 

PROVIDER: S-EPMC8310840 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature